Friday, October 01, 2021 6:52:22 AM
OWNER NAME DATE SHARES HELD CHANGE (SHARES) CHANGE (%) VALUE (IN 1,000S)
BLACKROCK INC. 06/30/2021 15,553,337 120,581 0.781% $16,487
VANGUARD GROUP INC 06/30/2021 10,449,703 -112,930 -1.069% $11,077
STATE STREET CORP 06/30/2021 3,846,390 914,209 31.178% $4,077
GEODE CAPITAL MANAGEMENT, LLC 06/30/2021 3,572,685
222,134 6.63% $3,787
NORTHERN TRUST CORP 06/30/2021 2,002,295 -186,878 -8.536% $2,122
SUSQUEHANNA INTERNATIONAL GROUP, LLP 06/30/2021 1,377,433 -117,856 -7.882% $1,460
NUVEEN ASSET MANAGEMENT, LLC 06/30/2021 968,383 357,962 58.642% $1,026
BANK OF NEW YORK MELLON CORP 06/30/2021 610,839 99,753 19.518% $647
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 06/30/2021 532,143 1,951 0.368% $564
SQUAREPOINT OPS LLC 06/30/2021 483,959 483,959 New $513
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 06/30/2021 297,557 -25,291 -7.834% $315
RHUMBLINE ADVISERS 06/30/2021 251,990 102,457 68.518% $267
EDMOND DE ROTHSCHILD HOLDING S.A. 06/30/2021 200,000 0 0% $212
JPMORGAN CHASE & CO 06/30/2021 185,760 -404,597 -68.534% $197
MARSHALL WACE, LLP 06/30/2021 170,524 170,524 New $181
This is just the first page showing the largest holders.
https://www.nasdaq.com/market-activity/stocks/ibio/institutional-holdings
Double bottom from January. See if it holds.
https://finviz.com/quote.ashx?t=IBIO
“Although we are pleased to have executed on our November promise to build a high-value oncology portfolio, we are even more pleased to deliver results in other areas of our Biopharmaceutical segment, especially our next-generation COVID-19 vaccine, IBIO-202. We believe that there is a critical need to design new vaccines that can target regions of the virus aside from the frequently mutating spike protein, in order to address the looming risk of an escape variant. IBIO-202 could potentially represent one such option, given that it targets the more highly conserved nucleocapsid protein of SARS-CoV-2, and in preclinical models of disease, drove robust memory T cell responses. We look forward to updating investors on IBIO-202 after we receive feedback on our pre-IND package, which was submitted earlier this month.”
Based on current plans, iBio believes the current cash position is sufficient to fund operations through the first calendar quarter of 2023.
https://finance.yahoo.com/news/ibio-reports-fourth-quarter-fiscal-113000770.html
To me, this looks to be an excellent entry point. I'm looking to accumulate even more.
IBIO daily chart
Do your research! Play the TA. All posts are my opinion.
Is fundamental trading dead?
"We hope not." Richard Dennis
Recent IBIO News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:08:04 PM
- iBio Closes Sale of Manufacturing Facility in Texas • GlobeNewswire Inc. • 06/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 10:55:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:32:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:30:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:14:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:08:29 PM
- iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/13/2024 08:05:00 PM
- iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases • GlobeNewswire Inc. • 03/27/2024 11:00:00 AM
- iBio Announces $15.0 Million Private Placement • GlobeNewswire Inc. • 03/26/2024 11:35:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:59:30 PM
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka • GlobeNewswire Inc. • 02/26/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:36:09 PM
- iBio Announces Participation in 23rd Annual PepTalk Conference • GlobeNewswire Inc. • 01/16/2024 01:15:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 06:24:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 09:30:59 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/04/2024 01:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 12:44:38 PM
- iBio Amends and Extends Maturity of Credit Agreement • GlobeNewswire Inc. • 12/26/2023 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 09:17:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:13:08 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/06/2023 01:59:51 PM
- iBio, Inc. Announces Pricing of $4.5 Million Public Offering • GlobeNewswire Inc. • 12/05/2023 01:00:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM